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ABSTRACT The pharmacokinetics of progesterone (dose: 10
jig per animal) were studied in blood and cerebrospinal fluid of
adult ovariectomized rhesus monkeys after the administration of
the steroid as an intravenous injection, intravenous infusion (du-
ration of infusion: 10 min), or nasal spray. The bioavailability of
progesterone, in terms of area under the time-concentration
curve and the maximal concentration in the two body fluids, was
significantly higher when the steroid was infused or sprayed in-
tranasally than when it was injected intravenously. The clearance
of the steroid from the serum, as estimated by its elimination rate
constant, elimination half-life, and total body clearance, did not
differ for the three methods ofadministration. These findings sug-
gest that the bioavailability of progesterone is enhanced by ex-
tending the duration over which the steroid is delivered into the
hemal circulation.
Reports from our laboratories have shown that marked neu-
roendocrine effects leading to an impairment of ovarian (1) or
testicular (2) functions occur after the intranasal spraying ofpro-
gesterone in extremely low doses likely to be ineffective when
administered by oral or systemic routes. It has been suggested
(3) that these marked effects observed with low doses of the
steroid administered by an unconventional route may be related
to the rapid and preferential transfer of the steroid to the brain
via the cerebrospinal fluid (CSF). This suggestion is based on
the finding of much higher levels of progesterone in the CSF
after its being sprayed intranasally in comparison with its sys-
temic administration (4, 5).
Because the pharmacological effects of a drug are known to
be related to its bioavailability to target tissues rather than to
its administered dose, it was felt that a comparison of the phar-
macokinetics of progesterone after its systemic administration
and intranasal spraying would be useful in furthering our un-
derstanding of these unique, low-dose effects occurring upon
administering the steroid by an unconventional method. The
studies reported here were carried out to obtain such data with
particular reference to the bioavailability ofprogesterone to tis-
sues bathed by blood, CSF, or both after the administration of
progesterone by three different methods: intravenous (i.v.) in-jection, i.v. infusion, and nasal spray (n.s.).
MATERIALS AND METHODS
Animals. Six healthy adult female rhesus monkeys of similar
body weights (5-6.5 kg) and sizes (6) were selected from the
Primate Research Facility of our institute (7). These animals
consistently exhibited ovulatory menstrual cycles ofnormal du-
ration (23-28 days) before they were ovariectomized. They
were used 2 months after ovariectomy. The clinical condition
of all the animals, with particular reference to their liver and
renal functions, as evaluated by estimating blood or serum lev-
els of proteins, albumin, bilirubin, alkaline phosphatase, glu-
tamic-oxaloacetic transaminase, glutamic-pyruvic transami-
nase, urea, and creatinine were within normal values reported
for this species (8). The animals remained in good health
throughout the course of the present study.
Reagents. Analytical grade reagents, and doubly glass-dis-
tilled ethanol and water were used. Crystalline progesterone
was obtained from Sigma and the progesterone antiserum was
supplied by the World Health Organization under their Quality
Control Programme for Radioimmunoassay of Reproductive
Hormones (9).
Experimental Design. Progesterone was formulated in
ethanol/propylene glycol/water, 3:3:4 (vol/vol), and adminis-
tered at a dose of 10 jig by each of the following three routes:
i.v. injection, i.v. infusion, or n.s. The infusion was carried out
by using a model 351 syringe pump (Sage Instruments, Cam-
bridge, MA) at a uniform rate of 1 pug of progesterone per min-
ute for a total of 10 min. Five micrograms of progesterone was
sprayed over a period of 10 sec into each nostril by using a com-
mercially available glass atomizer as described and illustrated
previously (3, 10).
The antecubital vein was used for the systemic administration
of the steroid, and blood samples were drawn from the sa-
phenous vein. Samples of clear free-flowing CSF were drawn
from the cisterna magna as described (11).
All six of the animals were subjected to the three methods
of progesterone administration in sequence (Table 1). The an-
imals were anesthetized before progesterone was administered
and they remained anesthetized throughout the period of sam-
pling the body fluids. The animals were rested for 2 weeks
between experiments and their diet was supplemented with
hematinics.
Estimation of Progesterone. Progesterone was estimated in
the two body fluids by specific radioimmunoassay as described
(12, 13). The coefficients ofvariation within and between assays
were, respectively, 7.12 ± 1.26% and 9.45 ± 1.04%.
Pharmacokinetic Parameters. A two-compartment kinetic
model with first-order absorption and clearance (14) was as-
sumed to determine the following parameters (15). Each of
these parameters was obtained separately for individual mon-
keys and the data are expressed as geometric mean values with
95% confidence limits for each of the treatment groups.
Area under time-concentration curve (A UC). AUC was cal-
Abbreviations: CSF, cerebrospinal fluid; i.v., intravenous; inf, infusion;
n.s., nasal spray; AUC, area under curve.
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Table 1. Distribution of six ovariectomized monkeys into three
groups of three animals each for sequential administration of
progesterone by diverse methods
Sequence of methods of
Monkey administration
Group nos. 1 2 3
A 912,981,986 i.v. inf n.s.
B 886,1005,1030 n.s. i.v. inf
C* 912, 981,986 inf n.s. Lv.
i.v., Intravenous injection; inf, intravenous infusion.
* Only six animals of similar body weights were available for the pres-
ent study. Monkey nos. 912, 981, and 986 were used twice. However,
analyses of data based only on groups A and B or B and C provided
the same statistical significance.
culated by using the trapezoidal rule (16) according to the fol-
lowing formula (17):
n-1
AUC = 1/2 > {y(i + 1) + y(i)}-{t(i + 1) - Oil
i= 1
in which n is the number of experimental points, y(i) is the ith
serum/CSF sample, and t(i) is time of the ith sample.
AUC for serum and CSF was calculated between 0 and 60
min. The AUC for serum between 0 and X0 min was calculated
by using the formula
AUC =AUCG +-6
in which C60 is the concentration ofprogesterone at 60 min and(3 is the elimination rate constant.
AUC~f could not be calculated for CSF because progester-
one levels in the CSF obtained at the different time intervals
in the present study did not show a progressive decline in all
the individuals for estimating the elimination rate constant.
Concentration of progesterone. The maximal concentration
(CmJ) and the time of maximal concentration (Tm.) were esti-
mated from a graph in which mean concentrations of proges-
terone in the serum or CSF were plotted against time.
Elimination rate constant ((3). 3 was determined by linear
regression analysis of the serum decay curve after the i.v. in-jection. The last three data points in 15, 30, and 60 min showed
a linear decline and hence these points were taken for calcu-
lating (3.
Elimination half-life (t1,2(3). This was calculated by using the
relationship
0.693
t1/2 a = 83
Apparent volume ofdistribution (V,). Vd was estimated from
the relationship
i.v. dose
Vd =
co
in which C0 is concentration of progesterone in serum at 0 min
obtained by extending the regression line to the y axis for data
obtained after i.v. injection of progesterone.
Apparent total body clearance (CITB). C1TB was calculated
from the relationship
CITB = VdJ3
Calculations. The pharmacokinetic data were subjected to
analysis of variance by using a model 700 Wang programmable
calculator. This analysis was followed by the Newman-Keul
multiple range test of significance (18).
RESULTS
General. In marked contrast to the systemic administration
of progesterone, in which the entire amount of the predeter-
mined dose of the steroid was delivered directly into the blood
circulation, spraying progesterone into one of the nostrils with
a glass atomizer resulted in the unavoidable loss ofsome of the
steroid contained in the atomized spray escaping through the
other nostril. Thus, it was not possible to precisely estimate the
actual amount ofthe steroid actually deposited in the nasal cav-
ities. Because the predetermined dose of 10 pg ofprogesterone
was delivered into the nostrils it is most likely that the actual
amount of progesterone deposited within the nasal cavities was
much less than 10 pg.
Concentrations of Progesterone in the Serum. Progesterone
concentrations declined progressively in samples taken at dif-
ferent intervals after the i.v. or n.s. administration of proges-
terone. After i.v. infusion, progesterone concentrations showed
a marked increase in the second sample (9 min) as compared
with the initial sample (3 min), but the concentrations declined
progressively in samples taken after the cessation ofthe infusion
at 10 min.
Progesterone concentrations in serum samples taken at 3 min
were not significantly different for the three methods ofadmin-
istration. However, in all subsequent samples concentrations
ofprogesterone were significantly higher after i.v. infusion and
n.s. as compared with its i.v. injection; serum concentrations
ofprogesterone did not differ significantly between i.v. infusion
and n.s. (Table 2).
Concentrations of Progesterone in the CSF. Progesterone
concentrations after its i.v. injection showed a progressive de-
cline in samples taken at different intervals. After i.v. infusion
Table 2. Progesterone concentrations in serum samples taken at different intervals after administration by
diverse methods
Analysis of variancet
Time, Progesterone, nM i.v. vs. i.v. vs. inf vs.
min i.v. inf n.s. inf n.s. n.s.
3 4.79 (3.98-5.76) 5.43 (4.33-6.82) 5.45 (4.41-6.73) NS NS NS
9 3.83 (2.77-5.30) 7.15 (5.96-8.58) 5.31 (4.71-5.98) ** * NS
15 2.59 (2.01-3.33) 4.41 (3.79-5.11) 4.59 (3.88-5.42) ** ** NS
30 2.05 (1.47-2.87) 3.37 (2.80-4.05) 3.16 (2.67-3.73) * * NS
60 1.55 (1.10-2.24) 2.41 (1.86-2.55) 2.17 (1.86-2.55) * * NS
Data are presented as geometric mean concentrations with 95% confidence limits in parentheses (n = 9). Values obtained
in samples taken from individuals at 0 min-i.e., just prior to the administration of the steroid-have been subtracted from
the values obtained for the same individual at different time intervals of sampling serum both here and in subsequent cal-
culations. The 0 min values showed a range between 0.64 and 1.70 nM.
t One-way analysis of variance followed by multiple range test (18). NS, not significant; *, P < 0.05; **, P < 0.01.
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Table 3. Progesterone concentrations in CSF samples taken at different intervals after administration by
diverse methods
Analysis of variancet
Time, Progesterone, nM i.v. vs. i.v.vs. inf vs.
min i.v. inf n.s. inf n.s. n.s.
3 0.19 (0.15-0.24) 0.25 (0.17-0.35) 0.18 (0.11-0.28) NS NS NS
9 0.17 (0.12-0.24) 0.42 (0.26-0.67) 0.37 (0.28-0.48) ** ** NS
15 0.17 (0.13-0.22) 0.58 (0.38-0.88) 0.35 (0.24-0.51) ** NS
30 0.10 (0.05-0.18) 0.34 (0.23-0.51) 0.23 (0.10-0.51) * NS NS
60 0.04 (0.01-0.12) 0.23 (0.13-0.41) 0.18 (0.11-0.28) * * NS
Data are presented as geometric mean concentrations with 95% confidence limits in parentheses (n = 9). Values have been
corrected as described for Table 2 both here and in subsequent calculations. The 0 min values showed a range between 0.06
and 0.24 nM.
t One-way analysis of variance followed by multiple range test (18). NS, not significant; *, P < 0.05; **, P < 0.01; ***, P <
0.001.
the concentrations of progesterone increased in the first two
samples, taken at 3 and 9 min, and thereafter the levels declined
progressively. When progesterone was sprayed intranasally, its
concentrations in the second and third CSF samples (9 and 15
min) were higher as compared with the first samples (3 min).
The levels of the steroid declined progressively in the fourth
and fifth samples (30 and 60 min) (Table 3).
Progesterone concentrations in CSF samples taken at 3 min
were not significantly different for the three methods ofadmin-
istration. In all subsequent samples, however, progesterone
concentrations were significantly higher after i.v. infusion and
n.s. as compared with i.v. injection. CSF concentrations ofpro-
gesterone did not differ significantly between i.v. infusion and
n.s. (Table 3).
Pharmacoldnetics of Progesterone in the Serum. Data ob-
tained for the various pharmacokinetic parameters and the lev-
els of statistical significance of the differences in these param-
eters between the three methods ofadministering progesterone
are shown in Table 4.
A comparison of the data obtained for AUCf ', AUCf',
Cmax, and Tmax among the three methods of administering the
steroid clearly indicates that the values obtained for i.v. infusion
were the highest, followed by those obtained by n.s. and i.v.
injection.
A statistical comparison of the AUCfJ° and AUCfJ' between
i.v. injection and i.v. infusion or between i.v. injection and n.s.
showed that the higher values obtained for the i.v. infusion and
n.s. were significantly different from the value observed for i.v.
injection. The slight differences observed in the AUCs between
the i.v. infusion and n.s. were not statistically significant.
The Cmax values for i.v. injection and i.v. infusion were sig-
nificantly different, whereas the Cm. values for i.v. injection
and n.s. or for i.v. infusion and n.s. were not.
Tm. values were significantly different for i.v. injection and
i. v. infusion but were not significantly different for comparisons
of i.v. infusion and n.s. or i.v. injection and n.s.
Although the (3, t112f3, and ClTB values showed slight differ-
ences among the three routes of administering progesterone,
these differences were not statistically significant.
Pharmacokinetics of Progesterone in CSF. The values ob-
tained for the AUC~o,Cmax, and Tm. were highest after i-v.
infusion of progesterone, followed by those obtained after n.s.
and i.v. injection. A comparison of all these parameters among
the three methods of progesterone administration showed that
statistically significant differences were evident between i.v.
injection and i.v. infusion as well as between i.v. injection and
n.s. but were not evident between i.v. infusion and n. s. (Table
5).
Linear Regression Analysis. In a linear regression analysis
of progesterone concentrations in serum vs. those in CSF after
diverse methods of administering the steroid, a highly signifi-
cant correlation coefficient was obtained with the i.v. injection;
the correlation coefficients obtained with i.v. infusion and n.s.
were not statistically significant (Table 6).
DISCUSSION
The pharmacokinetics of endogenously produced progesterone
have been extensively investigated and reviewed (19-21), but
comparable data for exogenously administered progesterone are
not available. The present study has thrown some light on the
pharmacokinetics ofprogesterone after its systemic administra-
tion. Besides providing such information, the present studies
have shown that the detectable levels ofprogesterone in serum
Table 4. Pharmacokinetics of progesterone in the serum after its administration by diverse methods to ovariectomized monkeys
Analysis of variancet
Pharmacokinetic iv. vs. iv. vs. inf vs.
parameter i.v. inf n.s. inf n.s. n.s.
AUCfr, nM-min 144.74 (112.32-186.53) 230.30 (203.97-260.03) 213.45 (186.00-244.95) ** ** NS
AUCf, nM-min 203.33 (179.52-230.30) 408.13 (337.51-493.53) 371.19 (313.40-439.64) ** ** NS
C1m., nM 5.05 (3.97-6.42) 7.57 (6.55-8.75) 6.00 (5.13-7.02) * NS NS
Tn,, min 3.83 (2.79-5.25) 8.92 (6.58-12.09) 5.52 (3.78-8.06) ** NS NS
8, min'1 0.196 (0.129-0.0299) 0.0135 (0.0104-0.0175) 0.152 (0.0114-0.0205) NS NS NS
t4/20, min 35.21 (23.11-53.65) 50.94 (39.19-66.12) 45.27 (33.79-60.66) NS NS NS
ClTB, liters-min-' 0.15 (0.10-0.23) 0.11 (0.08-0.15) 0.13 (0.08-0.19) NS NS NS
Vd, liters 8.14 (6.34-10.45)
Data are presented as geometric mean values with 95% confidence limits in parentheses (n = 9).
t Analysis of variance followed by multiple range test (18). NS, not significant; *, P < 0.05; **, P < 0.01.
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Table 5. Pharmacokinetics of progesterone in CSF after its administration by diverse methods to ovariectomized monkeys
Analysis of variancet
Pharmacokinetic i.v vs. i.v. vs. inf vs.
parameter iv. inf n.s. inf n.s. n.s.
AUCf0, nM-min 8.48 (6.51-10.95) 22.41 (15.59-32.19) 16.30 (10.28-25.84) ** * NS
CQmslx nM 0.2285 (0.1653-0.3158) 0.6579 (0.447-0.9669) 0.5336 (0.3546-0.8027) ** ** NS
T,,,, min 5.91 (3.33-10.49) 13.66 (10.63-17.57) 10.20 (6.82-15.25) * * NS
Data are presented as geometric mean values with 95% confidence limits in parentheses (n = 9).
t Analysis of variance followed by multiple range test (18). NS, not significant; *, P < 0.05; **, P < 0.01.
and CSF as well as its bioavailability in terms ofAUC and Cm,,
in both the body fluids differ markedly depending on the
method of administering the compound.
The AUC and Cm, of progesterone in the two body fluids
were significantly enhanced when the steroid was delivered
over an extended period oftime as an i. v. infusion in comparison
with a comparable dose being almost instantaneously delivered
as a bolus into the systemic circulation 'by i.v. injection. 'Inter-
estingly, the clearance of the steroid from serum as estimated
by determining 1, t112(, and C1TB did not differ significantly
between i.v. injection and i.v. infusion. These findings suggest
that the enhancement in the levels of progesterone as well as
the amplification of its bioavailability in the body fluids may be
related to the duration over which the steroid enters the blood
circulation rather than to differences in its clearance rates
among different methods of its administration. More studies
are, however, necessary to define in precise mathematical
terms the relationship between the duration of administering
into the systemic circulation and the amplification ofits bioavail-
ability.
The values obtained for the concentrations of progesterone
and .its bioavailability in the body fluids after the intranasal
spraying of the compound-were significantly higher than those
observed after i.v. injection. Though the values obtained after
n.s. were lower than those obtained after i.v. infusion, these
values were not significantly different. It must, however, be
noted that the actual amount of the steroid deposited into the
nasal cavity was much less than that administered by the sys-
temic routes.
Because progesterone sprayed into the nostrils would be de-
posited onto the nasal mucosa the question arises as to how can
such "topically".administered steroid show bioavailability val-
ues that are much higher than the values observed after its di-
rect injection into the venous blood. Studies -involving radio-
nuchde imaging techniques have shown that most of the
substances sprayed into the nostrils are deposited on the olfac-
tory mucosa (10). Electron microscopic studies of colloidal gold
particles sprayed onto the olfactory mucosa have shown that
these particles are pinocytosed by both the olfactory dendrites
and the adjoining supporting cells of the olfactory epithelium.
Substances entering each ofthese two cell types are transported
separately to different destinations. Particles entering the ol-
Table 6. Linear regression of progesterone concentrations in
serum (x axis) and CSF (y axis) after administration of the
steroid by diverse methods (45 xy pairs)
-Regression
parameter i.v. inf n.s.
Slope 0.027 0.010 0.023
y intercept 0.070 0.394 0.244
Correlation coefficient 0.551 0.066 0.104
t 4.329* 0.434 0.685
*,P <0.001.
factory dendrites are transported across the olfactory neuron
into the fila olfactoria. It has been suggested (10) that diffusable
substances, such as steroids, could traverse the olfactory nerves
and enter the CSF present in the perineural space surrounding
these nerves; this CSF is in communication with the CSF pres-
ent in the subarchnoid spaces. Substances pinocytosed by the
supporting cells are transported directly into the subepithelial
blood capillaries (10).
These morphological studies have traced the pathways by
which particulate materials are transported into the body fluids
across the olfactory mucosa, but the question as to whether lipo-
philic substances, such as progesterone in solution, also enter
the olfactory mucosa by pinocytosis or-by simple diffusion needs
to be determined.
Be that as it may, progesterone entering the olfactory mucosa
by pinocytosis or by simple diffusion will enter the body fluids
at a much slower rate than progesterone injected as a bolus
directly into the systemic circulation. It is therefore not sur-
prising that the levels and bioavailability ofprogesterone in the
body fluids after its being administered by n.s. is greater than
those observed after i.v. injection, as has been observed when
the steroid is infused over an extended period of time.
Thus, the present studies have shown that the concentrations
of progesterone and its bioavailability differ markedly with dif-
ferent methods of administration. These studies also offer an
explanation for the marked pharmacological effects observed
after the intranasal spraying of extremely low doses of proges-
terone (22, 23). The present studies also indicate the possibility
of administering physiological doses of progesterone as nasal
sprays for replacement therapy or contraceptive purposes.
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